Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around ...

Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s struggling partner ...

The mid-stage disappointment in Alzheimer’s disease delivers another blow to Neuphoria Therapeutics, which in November last year was forced to launch a strategic business review after a Phase 3 trial ...

A bipartisan House committee wants details on hundreds of clinical studies conducted at Chinese military facilities and in ...

By Deena Beasley June 30 (Reuters) - The chair of the U.S. House Select Committee on China opened national security ...

German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest ...

Merck inaugurates its Global Capability Centre in Bengaluru, enhancing digital innovation and collaboration across its global ...

Merck & Co. says it will settle a spate of lawsuits that blame the drugmaker’s blockbuster Gardasil cancer vaccine for causing autoimmune ailments that affect young women’s hearts and reproductive ...

A House committee wants answers from major drugmakers about their China clinical trial practices. The deadline is tighter ...

With pharma heavyweights clashing against one another and reeling in major sales in the ulcerative colitis (UC) | Merck is ...

Merck Korea said it celebrated the 40th anniversary of its facilities in Ansan, south of Seoul, where it produces semiconductor gases and chemicals.

Merck & Co. said a late-stage study of its autoimmune drug candidate tulisokibart in ulcerative colitis hit its key goals. Merck on Monday said the Phase 3 induction-only study met its primary ...